Subject ID | Treatment |
---|
5-FU + FA | FOLFIRI | FOLFOX |
---|
01 |
S
|
S
| S |
02a
| S | S |
I
|
03 |
S
| S | S |
04a
| R | I |
I
|
05a
| I | R |
R
|
06 | I |
N/D
| N/D |
07a
|
S
| I | I |
08a
| I |
I
|
I
|
09 | R |
S
|
S
|
10a
| I | R |
S
|
11 |
I
| R | I |
12a
| I |
I
| I |
13a
|
S
| I | I |
14 |
I
| I |
S
|
15a
| I | R |
R
|
16a
| I | R |
R
|
17a
| I | I |
R
|
18a
| R | S |
I
|
19a
|
R
| I | I |
- Results were categorized according to percentile thresholds (R = resistant < 25th percentile < I = intermediate sensitive < 75th percentile < S = sensitive; N/D = not determined). Oncogramme results for treatments that were actually given to patients are underlined
-
aIndicates the 13 patients selected for the supplementary analysis, which were those who received equivalent chemotherapeutic treatments over the course of at least two evaluations